Inactive Instrument

Constellation Pharmaceuticals, Inc.

CNST

US2103731061

Biotechnology & Medical Research

Constellation Pharmaceuticals, Inc.(NasdaqGS:CNST) dropped from Russell 2500 Growth Index

June 25, 2021 at 09:30 am IST

Latest news about Constellation Pharmaceuticals, Inc.

MorphoSys Out Licenses Pre-Clinical Oncology Program	07/22/07	CI
MorphoSys : Royalty Pharma Takes Equity Position in MorphoSys for $100 Million	17/21/17	MT
Sector Update: Health Care Stocks Lower Just Ahead of Closing Bell	16/21/16	MT
Sector Update: Health Care Stocks Lacking Much Traction	15/21/15	MT
Constellation Announces Management Changes	15/21/15	CI
Constellation Pharmaceuticals, Inc. Announces Resignation of Jigar Raythatha as Chief Executive Officer	15/21/15	CI
Constellation Pharmaceuticals, Inc. Announces Resignation of Emma Reeve as Chief Financial Officer	15/21/15	CI
DJ Industrial : Wall Street Futures Mostly Lower, Jobless Claims Drop Less Than Expected; Powell Speech Eyed	15/21/15	MT
Sector Update: Health Care Stocks Flat To Lower Pre-Bell Thursday	15/21/15	MT
MorphoSys : Finalizes $1.7 Billion Acquisition of Constellation Pharmaceuticals	15/21/15	MT
MorphoSys : Completes Tender Offer for Constellation Pharmaceuticals	15/21/15	MT
Constellation Pharmaceuticals, Inc.(NasdaqGM:CNST) dropped from NASDAQ Composite Index	15/21/15	CI
Constellation Pharmaceuticals, Inc.(NasdaqGS:CNST) dropped from S&P TMI Index	15/21/15	CI
Constellation Pharmaceuticals, Inc.(NasdaqGS:CNST) dropped from S&P Biotechnology Select Industry Index	15/21/15	CI
Constellation Pharmaceuticals, Inc.(NasdaqGS:CNST) dropped from S&P Global BMI Index	15/21/15	CI
MorphoSys AG completed the acquisition of Constellation Pharmaceuticals, Inc..	15/21/15	CI
Constellation Pharmaceuticals, Inc.(NasdaqGS:CNST) dropped from NASDAQ Biotechnology Index	14/21/14	CI
Constellation Pharmaceuticals, Inc.(NasdaqGS:CNST) dropped from Russell 2000 Growth Index	25/21/25	CI
Constellation Pharmaceuticals, Inc.(NasdaqGS:CNST) added to Russell 2000 Value Index	25/21/25	CI
Constellation Pharmaceuticals, Inc.(NasdaqGS:CNST) dropped from Russell Small Cap Comp Growth Index	25/21/25	CI
Constellation Pharmaceuticals, Inc.(NasdaqGS:CNST) added to Russell 2500 Value Index	25/21/25	CI
Constellation Pharmaceuticals, Inc.(NasdaqGS:CNST) dropped from Russell 3000 Growth Index	25/21/25	CI
Constellation Pharmaceuticals, Inc.(NasdaqGS:CNST) added to Russell 3000 Value Index	25/21/25	CI
Constellation Pharmaceuticals, Inc.(NasdaqGS:CNST) dropped from Russell 2500 Growth Index	25/21/25	CI
Constellation Pharmaceuticals, Inc.(NasdaqGS:CNST) added to Russell 3000E Value Index	25/21/25	CI

Chart Constellation Pharmaceuticals, Inc.

Duration

Period

Chart Constellation Pharmaceuticals, Inc.

More charts

Constellation Pharmaceuticals, Inc. discovers and develops small molecule therapeutics for the treatment of cancer, inflammatory/immunologic disorders and other diseases. The Company has three clinical-stage oncology development programs: the first program is evaluating a compound, CPI-0610, other program is evaluating a compound, CPI-1205 and CPI-0209 is initiate Phase I clinical trial and targeting solid tumors. CPI-1205 is a small molecule designed to promote anti-tumor activity by specifically inhibiting EZH2, an enzyme that suppresses target gene expression. CPI-0610 is a potent and selective small molecule designed to promote anti-tumor activity by selectively inhibiting the function of BET proteins, which are proteins that normally enhance target gene expression. The Company is conducting the ProSTAR trial, which is an open-label Phase Ib/2 clinical trial of CPI-1205 for the treatment of mCRPC in combination with enzalutamide and abiraterone acetate.

Sector

Biotechnology & Medical Research

More about the company

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
VERTEX PHARMACEUTICALS INCORPORATED	+9.42%	115B
REGENERON PHARMACEUTICALS, INC.	+11.84%	106B
BIONTECH SE	-14.15%	21.84B
ARGENX SE	-1.05%	21.96B
GENMAB A/S	-5.29%	19.21B
WUXI APPTEC CO., LTD.	-38.29%	17.71B
BEIGENE, LTD.	-4.16%	18.08B
NEUROCRINE BIOSCIENCES, INC.	+7.99%	14.32B
SAREPTA THERAPEUTICS, INC.	+36.24%	12.42B

Bio Therapeutic Drugs